March 27 (Reuters) – French drugmaker Sanofi said on Friday the European Medicines Agency has recommended the approval of a subcutaneous version of its blood cancer drug administered through an on-body injector.
Here are the details from the company’s statement:
(Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo)
Comments